Mind Medicine (MindMed) Inc., a late-stage clinical biopharma company developing novel therapies for brain health disorders, is pleased to announce the appointment of Brandi L. Roberts as Chief Financial Officer (CFO), effective June 2, 2025. In this role, Ms. Roberts will be one of the members of the executive leadership team and will be responsible for the company’s financial strategy, capital planning, accounting, investor relations and information technology. The appointment of Ms. Roberts is timely given the company’s continued advancement of the clinical and commercial development of its key candidate MM120 orally disintegrating tablet (ODT) for generalised anxiety disorder (GAD) and major depressive disorder (MDD).
Robert Barrow, CEO of MindMed said “ Brandi joins MindMed at a crucial moment for the company bringing with her a powerful combination of financial acumen, strategic vision, and deep biotech sector expertise bringing with her a powerful combination of financial acumen, strategic vision, and deep biotech sector expertise”. “Her proven track record leading public companies through transformative milestones, including initial public offerings (IPO), business development and investor engagement makes her a valuable addition to our organization. As we accelerate toward the potential commercialisation of MM120 ODT, her understanding of the healthcare landscape and executional strength will be instrumental in advancing our strategy, driving growth, and delivering long-term value for both patients and shareholders”.
Ms Roberts said, “MindMed is leading a true paradigm shift in mental health treatment, and I’m excited to collaborate with a team renowned for its exceptional depth and breadth of experience in drug development”.
Also read: A Step-by-Step Guide For Business Process Automation
With over 25 years of experience in financial leadership, Ms. Roberts served as CFO and EVP at Longboard Pharmaceutical, playing a key role in its IPO, multiple financings and $2.6 billion acquisition by Lundbeck in 2024. She has also been CFO at REVA Medical, Mast Therapeutics and Lineage Cell Therapeutics with finance roles at Pfizer. She has done her education in MBA from the University of San Diego, and a B.S. in Accounting and Finance from the University of Arizona. She also works as an advisory board member in the Association of Bioscience Financial Officers and also for Life Science San Diego.
